ERAS Protocols for Major Abdominal Surgery & the Role of Opioid vs. Non-Opioid Analgesics

1. What is ERAS and Why Does it Work?

• Up to 50% reduction in complication rates in colorectal surgery (Varadhan meta-analysis)
• Reduced length of stay, readmissions, and mortality
• Cost savings of $1,000-$8,700 per patient depending on surgery type
• 42% improved 5-year survival in high-compliance ERAS colorectal patients

2. The Three Phases of ERAS: Key Elements

A. Preoperative Phase

B. Intraoperative Phase

C. Postoperative Phase

3. Opioid vs. Non-Opioid Analgesia in ERAS - The Central Debate

"A central tenet of ERAS is multimodal opioid-sparing postoperative analgesia. Historically, opioids were the cornerstone of pain management in the postoperative period; however, there are growing concerns related to the risk of patients developing dependence on opioids during the postoperative period and ultimately becoming chronic users."

• Sabiston Textbook of Surgery, p. 379

Why Minimize Opioids?

1. Postoperative ileus (POI): Opioids bind peripheral µ-receptors in the gut wall, inhibiting GI motility. This is the dominant mechanism of POI after abdominal surgery, directly extending hospital stay.
2. Opioid dependence and the opioid crisis: 50% of patients report not filling their opioid prescriptions post-surgery, yet inappropriate prescribing by surgeons has contributed heavily to North America's opioid epidemic.
3. Dose-dependent side effects: PONV, sedation, urinary retention, respiratory depression, sleep disturbance - all of which conflict with ERAS goals of early mobilization and oral intake.

Multimodal Analgesic Strategy

Non-Opioid Analgesics in ERAS

1. Acetaminophen (Paracetamol)

• Often underestimated; provides sustained and equivalent analgesia compared with other perioperative analgesics when given regularly
• Can be given orally, rectally, or IV
• Opioid-sparing effect is inconsistent across studies, but its high safety profile makes it a routine ERAS component
• Administered on a scheduled basis (not PRN) - critical distinction

2. NSAIDs / COX-2 Inhibitors

• Provide anti-inflammatory, antipyretic, and analgesic effects
• Nonselective (ibuprofen, naproxen, diclofenac, ketorolac) inhibit COX-1 and COX-2
• Selective (celecoxib) inhibit mainly COX-2 with fewer GI and platelet effects
• Meta-analyses: IV diclofenac and ketorolac give good postoperative pain relief
• Important caveat: observational studies raised concern about anastomotic leakage with COX-2 inhibitors; one meta-analysis found no significant risk with ≤48h use, but risk may be elevated with >3 days of use or in emergency colorectal surgery
• Use with caution in: peptic ulcer disease, bleeding risk, CVD, renal/hepatic impairment

3. Thoracic Epidural Analgesia (TEA)

• Gold standard for open major abdominal surgery (colorectal, hepatic, esophageal, gastric)
• Placed at T7-T10; when covering T10 dermatome, it blunts adrenal catecholamine and cortisol release, directly reducing insulin resistance
• Provides excellent pain relief with minimal or no systemic opioids
• Supports return of bowel function by blocking sympathetic efferents to the gut
• Drawbacks: hypotension (may require vasopressors), failure rates up to 30%, contraindicated in coagulopathy
• For laparoscopic surgery, TEA benefit is less clear - abdominal wall blocks may be preferred

4. Transversus Abdominis Plane (TAP) Block

• Ultrasound-guided injection of local anesthetic (bupivacaine, ropivacaine) into the neurofascial plane between internal oblique and transversus abdominis
• Effective for somatic pain of abdominal wall incision
• TAP blocks performed before surgery appear to provide better analgesia than post-closure blocks
• Associated with decreased length of stay vs. systemic opioids in laparoscopic colorectal surgery
• Liposomal bupivacaine (extended-release) formulations show promising results

5. IV Lidocaine Infusion

• Systemic IV lidocaine (1-1.5 mg/kg/h) has anti-inflammatory and analgesic properties
• Reduces postoperative pain scores, opioid consumption, and time to first bowel movement
• Considered an alternative when neuraxial/regional techniques are not feasible

6. Ketamine (Sub-anesthetic doses)

• N-methyl-D-aspartate (NMDA) receptor antagonist
• Prevents central sensitization ("windup")
• Used intraoperatively (0.1-0.5 mg/kg bolus) or as low-dose infusion (0.1-0.2 mg/kg/h)
• Recent systematic review (PMID 41814842, 2026) confirms perioperative ketamine/esketamine supports ERAS goals
• Particularly useful in opioid-tolerant patients

7. Dexamethasone

• Dual role: PONV prophylaxis + analgesic (reduces peripheral inflammation)
• Single dose 8mg IV preoperatively is standard ERAS practice

8. Magnesium

• NMDA antagonist; reduces opioid consumption perioperatively
• Often given as IV infusion intraoperatively

9. Dexmedetomidine / Clonidine

• Alpha-2 agonists; reduce opioid requirements and sympathetic activation
• Dexmedetomidine useful for sedation without respiratory depression in PACU

10. Neuraxial (Intrathecal) Opioids

• Single-shot intrathecal morphine (0.1-0.3 mg) provides 12-24h of excellent visceral analgesia
• Lower doses than systemic opioids; avoids ileus better than IV opioids
• Respiratory depression risk - requires monitoring
• Used where epidural catheter is not practical

Role of Opioids in ERAS

• Short-acting intraoperative opioids (fentanyl, remifentanil, sufentanil) are still used for intraoperative nociception but at the lowest effective dose
• Patient-controlled analgesia (PCA) with IV morphine or hydromorphone serves as rescue for breakthrough pain
• Oral opioids (oxycodone, tramadol) are used as step-down after multimodal non-opioid therapy is maximized
• The goal is opioid sparing, not opioid elimination - most ERAS protocols prescribe opioids PRN as rescue only, not scheduled

4. Surgery-Specific ERAS Highlights

5. ERAS Outcomes Evidence

• Colorectal surgery (Varadhan meta-analysis): Complication rates reduced by up to 50% with ERAS compliance
• Liver surgery RCT meta-analysis: Significantly reduced morbidity, faster functional recovery, shorter LOS
• Pancreatic surgery: >80% ERAS compliance associated with significantly reduced mortality and major complications
• Esophageal, gastric, bariatric surgery: Similar benefits confirmed

6. Recent Evidence Updates (PubMed, 2024-2026)

• Perioperative Ketamine/Esketamine for ERAS (PMID 41814842, J Invest Surg 2026): Systematic review confirms ketamine and esketamine support opioid-sparing goals within ERAS pathways
• Ketamine in Bariatric Surgery Multimodal Analgesia (PMID 41840313, Obes Surg 2026): Meta-analysis of RCTs confirms opioid-sparing benefits in bariatric ERAS
• The ERAS Society published updated colorectal surgery guidelines in 2024 (available open-access via erasociety.org)
• The 2026 ASA Practice Guideline on Perioperative Pain Management reinforces fascial plane blocks and regional techniques for abdominal surgery, showing moderate-quality evidence for reduced pain intensity and opioid consumption

Key Takeaway

1. Pre-emptive neuraxial blockade (TEA for open surgery) to blunt the neuroendocrine stress response
2. Scheduled non-opioid baseline analgesia (acetaminophen + NSAID/COX-2 inhibitor)
3. Targeted regional techniques (TAP block, wound infiltration, IV lidocaine)
4. Opioid adjuncts (ketamine, magnesium, dexmedetomidine) to minimize dose
5. Opioids only as rescue/PRN - not scheduled first-line